

Clinical Policy Title:	triheptanoin
Policy Number:	RxA.632
Drug(s) Applied:	Dojolvi®
Original Policy Date:	09/14/2020
Last Review Date:	8/28/2024
Line of Business Policy Applies to:	All line of business (except Medicare)

Criteria

I. Initial Approval Criteria

A. Long chain fatty acid oxidation disorders (LC-FAOD) (must meet all):

1. Diagnosis of LC-FAOD;
2. Member is not receiving Dojolvi® in combination with any other medium-chain triglyceride (MCT) product;
3. Target daily dosage does not exceed 35% of the patient’s total prescribed daily caloric intake.

Approval Duration

All Lines of Business (except Medicare): 12 months

II. Continued Therapy Approval

A. Long chain fatty acid oxidation disorders (LC-FAOD) (must meet all):

1. Member is currently receiving or has been treated with this medication within the past 120 days, excluding manufacturer samples
2. Target daily dosage does not exceed 35% of the patient’s total prescribed daily caloric intake.

Approval Duration

All Lines of Business (except Medicare): 12 months

References

Not applicable.

Review/Revision History	Review/Revised Date	P&T Approval Date
Policy established.	09/14/2020	09/14/2020
Policy was reviewed: <ol style="list-style-type: none"> 1. Initial Approval Criteria I.A.2 was updated to include prescriber criteria, “Prescribed by or in consultation with a metabolic disease specialist...”. 2. Continued Therapy Approval Criteria II.A.1 was rephrased to “Member is currently receiving medication that has been authorized by RxAdvance...”. 3. Continued Therapy Approval Criteria II.A.3 	06/28/2021	09/14/2021

This clinical policy has been developed to authorize, modify, or determine coverage for individuals with similar conditions. Specific care and treatment may vary depending on individual need and benefits covered by the plan. This policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. This document may contain prescription brand name drugs that are trademarks of pharmaceutical manufacturers that are not affiliated with RxAdvance.

was updated to include “Target daily dosage does not exceed 35%...”.		
Policy was reviewed.	04/05/2022	07/18/2022
Policy was reviewed: <ol style="list-style-type: none"> 1. Initial Approval Criteria, I.A.1: Updated diagnosis criteria from documented diagnosis of CPT I, CACT, CPT II, VLCAD, TFP, or LCHAD in long chain fatty acid oxidation disorders to Diagnosis of LC-FAOD (long chain fatty acid oxidation disorders). 2. Initial Approval Criteria, I.A.3: Updated to include new combination criteria Member is not receiving Dojolvi® in combination with any other medium-chain triglyceride (MCT) product. 	04/28/2023	07/13/2023
Policy was reviewed.	10/19/2023	10/19/2023
Policy was reviewed: <ol style="list-style-type: none"> 1. Removed prescriber restrictions. 2. Removed dose restrictions. 3. Updated Continued therapy approval with the new verbiage containing 120 days lookback period. 4. Removed reauthorization requirement for positive response to therapy. 5. Updated approval duration verbiage. 	8/28/2024	9/13/2024